Severity classification of Tenosynovial Giant Cell Tumours on MR imaging
- PMID: 30217317
- DOI: 10.1016/j.suronc.2018.07.002
Severity classification of Tenosynovial Giant Cell Tumours on MR imaging
Abstract
Aim: Current development of novel systemic agents requires identification and monitoring of extensive Tenosynovial Giant Cell Tumours (TGCT). This study defines TGCT extension on MR imaging to classify severity.
Methods: In part one, six MR parameters were defined by field-experts to assess disease extension on MR images: type of TGCT, articular involvement, cartilage-covered bone invasion, and involvement of muscular/tendinous tissue, ligaments or neurovascular structures. Inter- and intra-rater agreement were calculated using 118 TGCT MR scans. In part two, the previously defined MR parameters were evaluated in 174 consecutive, not previously used, MR-scans. TGCT severity classification was established based on highest to lowest Hazard Ratios (HR) on first recurrence.
Results: In part one, all MR parameters showed good inter- and intra-rater agreement (Kappa≥0.66). In part two, cartilage-covered bone invasion and neurovascular involvement were rarely appreciated (<13%) and therefore excluded for additional analyses. Univariate analyses for recurrent disease yielded positive associations for type of TGCT HR12.84(95%CI4.60-35.81), articular involvement HR6.00(95%CI2.14-16.80), muscular/tendinous tissue involvement HR3.50(95%CI1.75-7.01) and ligament-involvement HR4.59(95%CI2.23-9.46). With these, a TGCT severity classification was constructed with four distinct severity-stages. Recurrence free survival at 4 years (log rank p < 0.0001) was 94% in mild localized (n56, 1 recurrence), 88% in severe localized (n31, 3 recurrences), 59% in moderate diffuse (n32, 12 recurrences) and 36% in severe diffuse (n55, 33 recurrences).
Conclusion: The proposed TGCT severity classification informs physicians and patients on disease extent and risk for recurrence after surgical treatment. Definition of the most severe subgroup attributes to a universal identification of eligible patients for systemic therapy or trials for novel agents.
Keywords: Classification; Giant cell tumor of tendon sheath; Giant cell tumors; Giant cells; Magnetic resonance imaging; Neoplasms; Pigmented Villonodular Synovitis; Rare diseases; Tendons.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT.Surg Oncol. 2020 Dec;35:261-267. doi: 10.1016/j.suronc.2020.08.030. Epub 2020 Aug 26. Surg Oncol. 2020. PMID: 32932224
-
Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?Histopathology. 2019 Jan;74(2):332-340. doi: 10.1111/his.13744. Epub 2018 Nov 11. Histopathology. 2019. PMID: 30152874 Free PMC article.
-
Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.Lancet Oncol. 2019 Jun;20(6):877-886. doi: 10.1016/S1470-2045(19)30100-7. Epub 2019 Apr 24. Lancet Oncol. 2019. PMID: 31029509
-
Treatments of tenosynovial giant cell tumours of the temperomandibular joint: a report of three cases and a review of literature.Int J Oral Maxillofac Surg. 2018 Oct;47(10):1288-1294. doi: 10.1016/j.ijom.2018.04.001. Epub 2018 Apr 27. Int J Oral Maxillofac Surg. 2018. PMID: 29709323 Review.
-
Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence.Oncol Rep. 2000 Mar-Apr;7(2):413-9. Oncol Rep. 2000. PMID: 10671695 Review.
Cited by
-
Diffuse-Type Tenosynovial Giant Cell Tumor: What Are the Important Findings on the Initial and Follow-Up MRI?Cancers (Basel). 2024 Jan 17;16(2):402. doi: 10.3390/cancers16020402. Cancers (Basel). 2024. PMID: 38254890 Free PMC article. Review.
-
Prediction of local recurrence in tenosynovial giant cell tumor of the knee: Based on preoperative MRI evaluation into disease subtypes and severity.PLoS One. 2023 Jun 14;18(6):e0287028. doi: 10.1371/journal.pone.0287028. eCollection 2023. PLoS One. 2023. PMID: 37315053 Free PMC article.
-
MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment.Insights Imaging. 2023 Feb 1;14(1):22. doi: 10.1186/s13244-023-01367-z. Insights Imaging. 2023. PMID: 36725759 Free PMC article. Review.
-
A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis.J Surg Oncol. 2022 Dec;126(8):1520-1532. doi: 10.1002/jso.27067. Epub 2022 Aug 25. J Surg Oncol. 2022. PMID: 36006054 Free PMC article.
-
Unusual Uptake of [131I] in a Tenosynovial Giant Cell Tumour Relapse in a Patient with Differentiated Thyroid Cancer.Mol Imaging Radionucl Ther. 2022 Jun 27;31(2):145-147. doi: 10.4274/mirt.galenos.2021.40326. Mol Imaging Radionucl Ther. 2022. PMID: 35771035 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
